DocCheck AG (STU:AJ91) Debt-to-EBITDA : (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AJ91 DocCheck AG STU:AJ91
70 GF Score
Price €10.80
GF Value €9.26
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is DocCheck AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DocCheck AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.95 Mil. DocCheck AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €3.21 Mil. DocCheck AG's annualized EBITDA for the quarter that ended in Dec. 2025 was €12.13 Mil. DocCheck AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was 0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DocCheck AG's Debt-to-EBITDA or its related term are showing as below:

STU:AJ91' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.36   Max: 0.61
Current: 0.36

During the past 13 years, the highest Debt-to-EBITDA Ratio of DocCheck AG was 0.61. The lowest was 0.01. And the median was 0.36.

STU:AJ91's Debt-to-EBITDA is ranked better than
84.44% of 482 companies
in the Healthcare Providers & Services industry
Industry Median: 2.2 vs STU:AJ91: 0.36

DocCheck AG  (STU:AJ91) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DocCheck AG Debt-to-EBITDA Related Terms


DocCheck AG Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for DocCheck AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DocCheck AG Debt-to-EBITDA Chart

DocCheck AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DocCheck AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:AJ91 vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison

For the Health Information Services subindustry, DocCheck AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DocCheck AG Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DocCheck AG's Debt-to-EBITDA falls into.


STU:AJ91
70GF Score
DocCheck AG STU:AJ91
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DocCheck AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DocCheck AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.953 + 3.20889917) / 11.5380594
=0.36

DocCheck AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.953 + 3.20889917) / 12.13313326
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Is DocCheck AG (STU:AJ91) Overvalued in 2026?

Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued. The current stock price of €10.80 is trading 16.6% above its estimated GF Value™ of €9.26. GuruFocus considers DocCheck AG to be Modestly Overvalued.

Key valuation signals for STU:AJ91:

  • Debt-to-EBITDA:
  • GF Value™: €9.26 vs. price of €10.80 (16.6% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the STU:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DocCheck AG Business Description

Other Exchanges AJ91:Germany
Address Doccheck AG, Vogelsanger Strac E 66, Koln, DEU, 50823
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
70GF Score

Get the complete analysis for STU:AJ91

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€9.26
GF Value